The real effect of macitentan treatment

Macitentan (macitentan) is an endothelin receptor antagonist, mainly used to treat pulmonary arterial hypertension (PAH, WHO group 1). Its mechanism of action is by inhibiting endothelin-1 ( span>ET-1) binds to ETA and ETB receptors, thereby reducing vasoconstriction, fibrosis, inflammation and other pathological processes. ET-1 is overexpressed in patients with pulmonary arterial hypertension, leading to continued contraction and remodeling of blood vessels. By blocking this pathway, macitentan can improve pulmonary vascular resistance and delay disease progression. Clinical studies have shown that macitentan not only reduces patient mortality, but also reduces the need for intravenous or subcutaneous prostaglandins due to exacerbations and reduces hospitalization rates.

In terms of efficacy, the clinical research data of macitentan is relatively outstanding. A trial in patients with pulmonary arterial hypertension showed that patients taking 10 mg macitentan daily had a median pulmonary vascular resistance reduction of 37% and an increase in cardiac index, indicating that the drug can effectively improve hemodynamic indicators. In addition, the effect of macitentan is relatively long-lasting, and its metabolites still have certain pharmacological activities, further enhancing the therapeutic effect. Compared with other endothelin receptor antagonists, macitentan has relatively few adverse reactions. The most common adverse reactions include anemia, nasopharyngitis, bronchitis, headache and urinary tract infection, but most symptoms are mild and well tolerated by patients.

Macitentan has clear indications and is suitable for patients with WHOGroup 1pulmonary hypertension, especially those who require long-term treatment to delay disease progression. The recommended dose is 10 mg once daily, taken orally, without considering before or after meals, but do not break or chew to ensure stable release of the drug. It is worth noting that this drug is not suitable for patients with moderate to severe liver damage, and strict contraception is required when used in women of childbearing age because it has a clear risk of fetal teratogenesis.

In general, macitentan shows stable efficacy and good safety in the treatment of pulmonary hypertension, and can effectively improve the quality of life and prognosis of patients. However, due to its special mechanism of action and potential drug interactions, patients should use it under the guidance of a professional doctor and regularly monitor liver function, hemoglobin and other indicators to ensure the safety and effectiveness of treatment.

Reference materials:https://www.opsumit.com/